Acadian Asset Management
SRNE

Acadian Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Acadian Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29,895
Closed -$215K – 1836
2018
Q2 		$215K Sell
29,895
-89,129
-75% -$606K ﹤0.01% 1063
2018
Q1 		$613K Buy
119,024
+66,233
+125% +$471K ﹤0.01% 816
2017
Q4 		$200K Buy
+52,791
New +$137K ﹤0.01% 954

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Acadian Asset Management's SRNE Position: Q3 2018 in Review

Acadian Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2018, closing a stake of 29,895 shares — an estimated $215K sold.

Acadian Asset Management first reported a position in SRNE in Q4 2017 and held it in 3 quarters. The position peaked at $613K in Q1 2018. 97 funds tracked by Wall St. Rank hold SRNE as of Q3 2018.

  • Acadian Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Acadian Asset Management sold 29,895 Sorrento Therapeutics, Inc. shares in Q3 2018, an estimated $215K.
  • Acadian Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 3 quarters.
  • Acadian Asset Management's Sorrento Therapeutics, Inc. position peaked at $613K in Q1 2018.
  • 97 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2018.

Based on Acadian Asset Management's 13F filing for Q3 2018, filed 30 Oct 2018.